W. Geho

Diasome Pharmaceuticals, Inc. operates as a clinical stage diabetes therapeutics company which designs and develops insulin-based therapies for the treatment of diabetes. It focuses on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The company’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. The firm’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells. The company was founded by Len Rosenberg, Lance Converse, W. Blair Geho and Robert Geho in 2004 and is headquartered in Cleveland, OH.

SDG, Inc. is a privately held company based in Cleveland, OH. SDG is a developer of bio-nanotechnologies for use in drug delivery systems and in consumer product applications. The company's patented systems have been used in the creation and development of novel oral delivery systems for insulin, interferon, and other protein-based therapies, cell-receptor targeting of a wide variety of large and small molecule drugs and diagnostics, and consumer products ranging from hair conditioners and styling agents to skin-adhering insect repellents and sunscreens. These systems are ideally suited for use as cell receptor targeted vehicles in personalized medicine strategies for cancer. SDG's technologies have been tested in more than four hundred human subjects and have been shown to be both safe and efficacious in various disease categories, including diabetes and hepatitis. The company was founded by Robert Geho and W. Blair Geho.